Compare ARK Innovation ETF (ARKK) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Innovation ETF vs Inovio Pharmaceuticals Inc — how do they compare? ARK Innovation ETF trades at $81.5, while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: ARK Innovation ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ARKK | INO | |
|---|---|---|
52-Week High | $92.50 | $2.87 |
52-Week Low | $63.52 | $0.66 |
Market Cap | — | $78.55M |
Sector | — | Health |
Enterprise Value | — | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Innovation ETF (ARKK) trades at $81.37, up 1.13% with a bullish technical signal from moving averages. The fund faces mixed sentiment with Seeking Alpha highlighting concentration risks and underperformance versus S&P 500, while Cathie Wood continues aggressive buying in AI stocks like CoreWeave. Technical indicators show overbought conditions with RSI at 91 on the 6-day timeframe.
Outlook remains challenged by high fees (0.75%), concentrated bets on Tesla and SpaceX, and limited AI exposure. The fund's venture-style approach creates volatility, with 37.88% losses over five years. Near-term performance hinges on Tesla's 10% weighting and AI stock momentum amid decelerating revenue growth in portfolio companies.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
